Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Kiora Pharmaceuticals Inc. (KPRX)

Kiora Pharmaceuticals Inc. (KPRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium Newsfile - Thu Jul 2, 6:08AM CDT

Encinitas, California--(Newsfile Corp. - July 2, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that it will participate in an investor fireside chat at the Piper Sandler Virtual Ophthalmology...

KPRX : 2.55 (unch)
Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model Newsfile - Thu Jun 18, 6:04AM CDT

Data Presented at Epilepsy Foundation Pipeline Conference Demonstrated Significant Reduction in Epileptiform Activity: KIO-300 is the active pharmaceutical ingredient of KIO-301, Kiora's ongoing Phase...

KPRX : 2.55 (unch)
Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update Newsfile - Fri May 8, 10:46AM CDT

Encinitas, California--(Newsfile Corp. - May 8, 2026) - Kiora Pharmaceuticals (NASDAQ: KPRX) today reported financial results for the first quarter ended March 31, 2026, and provided an update on its clinical...

KPRX : 2.55 (unch)
Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway Newsfile - Tue Apr 14, 6:00AM CDT

Encinitas, California--(Newsfile Corp. - April 14, 2026) - Kiora Pharmaceuticals (NASDAQ: KPRX) today announced the publication of the results from its Phase 1 ABACUS-1 study of KIO-301 in Nature Medicine....

KPRX : 2.55 (unch)
Kiora Pharmaceuticals Announces Private Placement for Up to $24 Million Led by Perceptive Advisors Newsfile - Tue Apr 7, 6:06AM CDT

Sole investors are Perceptive Advisors (new) and ADAR1 Capital ManagementEncinitas, California--(Newsfile Corp. - April 7, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (the "Company"), today announced...

KPRX : 2.55 (unch)
Kiora Pharmaceuticals Announces Management Team Changes Newsfile - Thu Apr 2, 3:42PM CDT

Encinitas, California--(Newsfile Corp. - April 2, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced that Eric J. Daniels, M.D., MBA, will depart from his role...

KPRX : 2.55 (unch)
Kiora Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Results; Company Advances Retinal Disease Pipeline with Two Active Phase 2 Clinical Trials Newsfile - Wed Mar 25, 6:00AM CDT

Encinitas, California--(Newsfile Corp. - March 25, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced financial results for the fourth quarter and full year ended...

KPRX : 2.55 (unch)
Kiora Pharmaceuticals to Present at Oppenheimer's 36th Annual Healthcare Life Sciences Conference Newsfile - Thu Feb 19, 8:10AM CST

Encinitas, California--(Newsfile Corp. - February 19, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that the company will present at the Oppenheimer 36th Annual Healthcare Life Sciences...

KPRX : 2.55 (unch)
Retinal Disease Expert Dr. Taiji Sakamoto Joins Kiora Pharmaceuticals' Scientific Advisory Board Newsfile - Tue Jan 27, 6:16AM CST

Encinitas, California--(Newsfile Corp. - January 27, 2026) - Kiora Pharmaceuticals (NASDAQ: KPRX) has appointed leading retina specialist, Dr. Taiji Sakamoto, an expert in the treatment of retinal disease,...

KPRX : 2.55 (unch)
Kiora Pharmaceuticals Granted U.S. Patent Covering Additional Formulations for the KIO-100 Family of Anti-Inflammatory Compounds Newsfile - Mon Dec 1, 2025

Encinitas, California--(Newsfile Corp. - December 1, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that the U.S. Patent and Trademark Office issued a new patent (US-12,472,263) on...

KPRX : 2.55 (unch)

Barchart Exclusives

SMCI Stock Likely to Reverse from Oversold Levels as DCBBS Gains Growth Traction Barchart - Thu Jul 9, 3:49PM CDT
Supermicro announced a new partnership with Red Hat. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.